Page 13 - journal-9-2-Full

90 «“√ “√°“√·æ∑¬å·ºπ‰∑¬·≈–°“√·æ∑¬å∑“߇≈◊Õ° ªï∑’Ë 9©∫—∫∑’Ë 2°—𬓬π-∏—𫓧¡ 2554

9
4. ƒ∑∏‘Ï„π°“√∑”„À⇰‘¥Õ“°“√·æâ ·≈–Àâ“¡„™â„πºŸâªÉ«¬¡–‡√Áߺ‘«Àπ—ß ‡π◊ËÕß®“°¡’√“¬ß“π«à“‡Õ‡™’¬
58
®“°°“√∑¥ Õ∫°“√‡ªìπ “√°√–μÿâπ„À⇰‘¥°“√·æâ μ‘‚§‰´¥å∑’Ë∑“∫πº‘«ÀπŸ ∑”„À⇰‘¥‡π◊ÈÕßÕ°∫πº‘«Àπ—߉¥â
(sensitizer) ¢Õß “√ °—¥À¬“∫¢Õß∫—«∫°·≈– “√„π°≈ÿࡉ∑√ §«√À≈’°‡≈’ˬ߰“√√—∫ª√–∑“π¬“∫—«∫°μ‘¥μàÕ°—π‡ªìπ‡«≈“
‡∑Õ√åøïπÕ¬¥å ‰¥â·°à ‡Õ‡´’¬μ‘‚§‰´¥å, °√¥‡Õ‡´’¬μ‘°, °√¥¡“‡¥- π“π ‡æ√“–¡’√“¬ß“π«à“Õ“®∑”„À⇰‘¥æ‘…μàÕμ—∫‰¥â„πºŸâªÉ«¬∫“ß
64
·§ ‘°„πÀπŸμ–‡¿“ æ∫«à“ƒ∑∏‘Ï„π°“√‡ªìπ “√°√–μÿâπ„À⇰‘¥ √“¬
59
°“√·æâ∑’ËÕàÕπ¡“° Õ¬à“߉√°Áμ“¡ ¡’√“¬ß“π°“√‡°‘¥º◊Ëπ·æâ √–¡—¥√–«—ß°“√„™â√à«¡°—∫¬“∑’Ë¡’º≈μàÕμ—∫ ¬“¢—∫ªí “«–
67
—¡º— (allergic contact dermatitis) À≈—ß°“√„™âº≈‘μ¿—≥±å ·≈–¬“∑’Ë¡’º≈¢â“߇§’¬ß∑”„Àâßà«ßπÕπ ‡æ√“–Õ“®‡ √‘¡ƒ∑∏‘Ï°—π‰¥â
60-63
∑’Ë¡’ “√ °—¥∫—«∫°Õ¬ŸàÀ≈“¬√“¬ß“π ¥—ßπ—Èπ ºŸâ„™â¬“„™â¿“¬ ∫—«∫°Õ“®‡æ‘Ë¡√–¥—∫πÈ”μ“≈·≈–§Õ‡≈ ‡μÕ√Õ≈„π‡≈◊Õ¥
68
πÕ°À√◊Õ‡§√◊ËÕß ”Õ“ß∑’Ë¡’ “√ °—¥∫—«∫°‡ªìπ à«πª√–°Õ∫ ·≈–∑”„Àâª√– ‘∑∏‘º≈¢Õ߬“≈¥πÈ”μ“≈·≈–¬“≈¥‰¢¡—π≈¥≈ß
À≈—°®÷ߧ«√À¬ÿ¥„™âÀ“°¡’º◊Ëπ·æ⇰‘¥¢÷Èπ ‡π◊ËÕß®“°∫—«∫°¡’ƒ∑∏‘Ϭ—∫¬—È߇Õπ‰´¡å CYP2C9 ·≈–
5. §«“¡‡ªìπæ‘…μàÕμ—∫ CYP2C19 ®÷ߧ«√√–«—ß°“√„™â√à«¡°—∫¬“∑’Ë„™â‡Õπ‰´¡å‡À≈à“π’È„π
65,66
¡’√“¬ß“π°√≥’»÷°…“∑“ߧ≈‘π‘°«à“ºŸâªÉ«¬À≠‘ß 3 √“¬ °√–∫«π°“√‡¡·∑∫Õ≈‘´÷¡
Õ“¬ÿ 61, 52 ·≈– 49 ªï‡°‘¥¿“«–¥’´à“π À≈—ß√—∫ª√–∑“π∫—«∫°
Õ“°“√‰¡àæ÷ߪ√– ߧå
‡ªìπ‡«≈“ 30, 20 ·≈– 60 «—π μ“¡≈”¥—∫ ¡’§à“ ALT 1193,

1694 ·≈– 324 U/L §à“ ALP 503, 472 ·≈– 484 U/L §à“ ®“°°“√μ‘¥μ“¡‡Àμÿ°“√≥剡àæ÷ߪ√– ߧå∑’Ë®“°°“√„™â¬“
billirubin 4.23, 19.89 ·≈– 3.9 ¡°./¥≈. ºŸâªÉ«¬∑—Èß 3 √“¬¡’ ®“° ¡ÿπ‰æ√‚¥¬ ∂“∫—π°“√·æ∑¬å·ºπ‰∑¬√à«¡°—∫‚√ß
Õ“°“√¥’¢÷Èπ À≈—ßÀ¬ÿ¥√—∫ª√–∑“π∫—«∫° ·≈–‰¥â√—∫¬“ 欓∫“≈™ÿ¡™πμà“ß Ê 10 ·Ààß æ∫«à“∫—«∫°∑’Ë„Àâ‚¥¬°“√√—∫

ursodeoxycholic acid ´÷Ëß¡’§ÿ≥ ¡∫—쑇ªìπ anti-apoptotic ª√–∑“π Õ“®∑”„À⇰‘¥Õ“°“√§≈◊Ëπ‰ â Õ“‡®’¬π · ∫∑âÕß ¡«π
ºŸâªÉ«¬√“¬·√°‡¡◊ËÕ°≈—∫¡“√—∫ª√–∑“π∫—«∫°Õ’°§√—Èßæ∫«à“¡’°“√ ∑âÕß ∑âÕßÕ◊¥ ªí “«–∫àÕ¬ À√◊Õßà«ßπÕπ
64
∂Ÿ°∑”≈“¬¢Õßμ—∫‡°‘¥¢÷ÈπÕ’° à«πº≈‘μ¿—≥±å∫—«∫° ”À√—∫„™â¿“¬πÕ°Õ“®∑”„À⇰‘¥
60-63
6. Herb-Drug interaction º◊Ëπ·æâ —¡º— ‰¥â ¥—ßπ—Èπ À“°‡°‘¥Õ“°“√¥—ß°≈à“«§«√À¬ÿ¥
“√ °—¥∫—«∫°·≈– “√ÕÕ°ƒ∑∏‘Ï ¡’ƒ∑∏‘Ϭ—∫¬—È߇Õπ‰´¡å „™â¬“
CYP2C9, CYP2D6 ·≈– CYP3A4 ¥â«¬§«“¡·√ß∑’Ë·μ°μà“ß ‡Õ° “√Õâ“ßÕ‘ß

°—π ´÷Ë߇Õπ‰´¡å CYP2C9 ‡ªìπ isoform ∑’Ë∂Ÿ°¬—∫¬—È߉¥â¥’∑’Ë ÿ¥ 1. United States Department of Agriculture, Agricultural Research Service,
National Genetic Resources Program. Germplasm Resources
‚¥¬ “√∑’ˬ—∫¬—È߇Õπ‰´¡å‰¥âÕ¬à“ß¡’π—¬ ”§—≠ ‰¥â·°à °√¥‡Õ‡´’¬μ‘°
Information Network - (GRIN). Beltsville (MD): National Germplasm
“√ °—¥∫—«∫°¥â«¬‡Õ∑“πÕ≈ ·≈– “√ °—¥¥â«¬‰¥§≈Õ‚√¡’‡∑π Resources Laboratory. [cited 2011 Sep 20]. Available from: http://
www.ars-grin.gov/cgi-bin/npgs/html/taxon.pl?9831
πÕ°®“°π’È “√ °—¥™π‘¥À≈—ßπ’Ȭ—߬—∫¬—È߇Õπ‰´¡å CYP2C19
2. WHO Monographs on Selected Medicinal Plants. Vol. I. Geneva: World
‰¥âÕ’°¥â«¬ ¥—ßπ—Èπ °“√„™â∫—«∫°√à«¡°—∫¬“∑’Ë∂Ÿ° metabolize
Health Organization; 1999. p. 77-85.
¥â«¬‡Õπ‰´¡å CYP2C9 À√◊Õ‡Õπ‰´¡å CYP2C19 ®÷ßÕ“®∑”„Àâ 3. à«π惰…»“ μ√åªÉ“‰¡â ”π—°«‘™“°“√ªÉ“‰¡â °√¡ªÉ“‰¡â. ™◊ËÕæ√√≥
‰¡â·Ààߪ√–‡∑»‰∑¬ ‡μÁ¡ ¡‘μ‘π—π∑πå. ©∫—∫·°â‰¢‡æ‘Ë¡‡μ‘¡. °√ÿ߇∑æœ :
65,66
‡°‘¥Õ—πμ√°‘√‘¬“¢÷Èπ‰¥â
∫√‘…—∑ ª√–™“™π ®”°—¥; 2544. Àπâ“ 118.
4. ‚ ¿‘μ∫√√≥≈—°…≥å, ¢ÿπ. §—¡¿’√å·æ∑¬å‰∑¬·ºπ‚∫√“≥ ‡≈à¡ 1. °√ÿ߇∑æœ
¢âÕÀâ“¡„™â : ‚√ßæ‘¡æå ”π—°∑”‡π’¬∫𓬰√—∞¡πμ√’; 2513. Àπâ“ 66.
5. Supplement to Thai Herbal Pharmacopoeia. Nonthaburi: Department
Àâ“¡„™â∫—«∫°„πºŸâªÉ«¬∑’Ë·æâ ¡ÿπ‰æ√„π«ß»å Apiaceae of Medical Sciences, Ministry of Public Health; 2004. p. 9-17.
2 6. British Herbal Pharmacopoeia. Bournemouth: The British Herbal
(Umbelliferae)
Medicine Association; 1983. p. 56-7.
7. Newall CA, Anderson LA, Phillipson JD. Herbal medicines. London:
¢âÕ§«√√–«—ß The Pharmaceutical Press; 1996. p. 170-2.
8. Indian Herbal Pharmacopoeia. Vol. I. Mumbai: Indian Drug
§«√À≈’°‡≈’ˬ߰“√„™â§√’¡∫—«∫°μ‘¥μàÕ°—π‡ªìπ‡«≈“π“π Manufacturersû Association; 1998. p. 47-55.